| Respiratory System Neoplasm studied in …STUDIED_INderived200 of 11,608show all (up to 200) |
|---|
| → studied in | NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01770418Phase 1/Phase 2 · active not recruiting A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595944Phase 3 · active not recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391362NA · active not recruiting Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03793179Phase 3 · active not recruiting Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181060Phase 3 · recruiting Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04310007Phase 2 · active not recruiting Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04402788Phase 2/Phase 3 · suspended Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05642195Phase 1/Phase 2 · suspended Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05845671Phase 1/Phase 2 · active not recruiting Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987956Phase 2/Phase 3 · active not recruiting Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06448754Phase 2 · active not recruiting Volrustomig Priming Regimens Exploratory Phase II Platform Study · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06479811Phase 1 · recruiting [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06494241active not recruiting Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Respiratory System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06498635Phase 3 · recruiting Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694454Phase 1/Phase 2 · suspended Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06772623Phase 1/Phase 2 · recruiting Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06881784Phase 3 · recruiting Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07005297not yet recruiting Clinical Genetics Branch Eligibility Screening Survey · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Pulmonary Blastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07127874Phase 1 · recruiting A Study of PHN-012 in Patients With Advanced Solid Tumors · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07140315Phase 1 · recruiting DK222 Study at Hopkins · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07361484Phase 3 · not yet recruiting Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07388524Phase 3 · recruiting Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07472517Phase 3 · recruiting DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07509034Phase 1 · recruiting Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554339Phase 3 · recruiting A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578571Phase 1 · recruiting A Phase 1 Study of IM-1617 in Participants With Advanced Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07597070Phase 2 · not yet recruiting Universal Immunization to Fortify Immunotherapy Efficacy and Response · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671092early Phase 1 · recruiting Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705035Phase 1 · recruiting DBC-664 in Adult Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07707895Phase 1/Phase 2 · not yet recruiting DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07756840Phase 2 · not yet recruiting Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Respiratory System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830342Phase 1 · recruiting A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07845786Phase 2 · not yet recruiting Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07845916Phase 2 · not yet recruiting Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07846358Phase 1/Phase 2 · not yet recruiting This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847138NA · completed The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With Lung Cancer · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07848243Phase 2 · recruiting Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00034216recruiting Collection of Blood From Patients With Cancer · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00068003enrolling by invitation Harvesting Cells for Experimental Cancer Treatments · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01441089recruiting Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02146170recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04405401Phase 2 · terminated Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04487080Phase 3 · active not recruiting A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04988295Phase 3 · active not recruiting A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05388669Phase 3 · active not recruiting A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498428Phase 2 · recruiting A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05753722Phase 1 · completed A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06780098Phase 2 · recruiting Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06931717Phase 3 · recruiting A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07039474recruiting The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07099898Phase 3 · recruiting A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07144280Phase 3 · recruiting A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07190248Phase 3 · recruiting A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226999Phase 2/Phase 3 · recruiting Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07286149Phase 1/Phase 2 · recruiting A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07460440recruiting SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476287Phase 2 · recruiting Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07513376Phase 3 · recruiting A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07843940Phase 1/Phase 2 · not yet recruiting A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595931Phase 1 · active not recruiting M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02609776Phase 1 · active not recruiting Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03460977Phase 1 · recruiting A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03568656Phase 1/Phase 2 · completed Study to Evaluate CCS1477 in Advanced Tumours · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03702309recruiting Liquid Biopsy Evaluation and Repository Development at Princess Margaret · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04123379Phase 2 · active not recruiting Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253964Phase 2 · recruiting Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05132075Phase 3 · active not recruiting Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05269485Phase 2 · completed Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05430802Phase 2 · active not recruiting Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05488314Phase 1/Phase 2 · active not recruiting A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05647122Phase 1 · active not recruiting First in Human Study of AZD9592 in Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05663866Phase 2 · active not recruiting Premedication to Reduce Amivantamab Associated Infusion Related Reactions · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05908734Phase 1/Phase 2 · active not recruiting A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920356Phase 3 · recruiting A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06068049recruiting OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06116786Phase 1 · active not recruiting A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120140Phase 2 · active not recruiting Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06170788Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06172478Phase 2 · recruiting A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218914Phase 1 · recruiting Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312137Phase 3 · recruiting A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06383988NA · active not recruiting A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06579196Phase 1/Phase 2 · active not recruiting Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06667076Phase 2 · recruiting A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06667908Phase 2 · recruiting A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06758401Phase 3 · recruiting This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855524Phase 2 · recruiting Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868277Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06919874NA · recruiting Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06924606Phase 2 · terminated Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07037758Phase 1 · recruiting A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07154290Phase 2 · recruiting A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07155187Phase 2/Phase 3 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07183189Phase 3 · active not recruiting A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07222566Phase 3 · recruiting Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227025Phase 1/Phase 2 · recruiting A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227298Phase 1/Phase 2 · recruiting Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07230691recruiting A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07282444NA · not yet recruiting A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07360743Phase 2 · recruiting Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489066Phase 2 · recruiting Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07579221Phase 1/Phase 2 · recruiting Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07586202Phase 2 · recruiting A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07647094Phase 2 · recruiting A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07659782Phase 2 · recruiting A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07663630Phase 1 · not yet recruiting A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07670312Phase 1/Phase 2 · recruiting Evaluation of XYA02 in Patients With Advanced Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07761351Phase 4 · recruiting A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07841106Phase 2 · not yet recruiting Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases. · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07841249recruiting Cardiorespiratory Fitness After Lobectomy Versus Sublobar Resection · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07842471Phase 2 · not yet recruiting Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02293954NA · active not recruiting Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03191149Phase 2 · recruiting Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04340882Phase 2 · active not recruiting Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624204Phase 3 · active not recruiting Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04844073Phase 1/Phase 2 · terminated A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215340Phase 3 · active not recruiting Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05363319recruiting An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05717998active not recruiting Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06096844Phase 3 · recruiting Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06424327recruiting A Registry for People With Lung Cancer · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06447662Phase 1 · active not recruiting A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06605404recruiting Pan-tumor MRD Study · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06799286Phase 1 · completed A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890598Phase 3 · recruiting Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07465757Phase 2 · recruiting A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07559929Phase 1/Phase 2 · recruiting A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07565987NA · not yet recruiting The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833202Phase 3 · not yet recruiting A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838519NA · enrolling by invitation Personalizing Veterans' Lung Cancer Screening and Diagnosis · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838532completed Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07839325NA · not yet recruiting MIND-WELL Intervention · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00242723recruiting Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03340506Phase 4 · recruiting Dabrafenib and/or Trametinib Rollover Study · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03381274Phase 1/Phase 2 · active not recruiting Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04044859Phase 1 · active not recruiting ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04062708Phase 2 · active not recruiting CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05061550Phase 2 · recruiting Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05144997Phase 4 · active not recruiting Lorlatinib Continuation Study · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05312840Phase 2 · completed Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05607108Phase 2 · recruiting A Study of ZEN003694 in People With Squamous Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715229Phase 2 · terminated Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253520Phase 1 · active not recruiting Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06337552NA · active not recruiting High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357533Phase 3 · recruiting Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06452277Phase 3 · recruiting A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06491862recruiting RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561386Phase 3 · recruiting A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564844Phase 3 · active not recruiting A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06618287Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627647Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07063745Phase 2/Phase 3 · recruiting A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07140016Phase 1 · recruiting A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07155174Phase 2 · recruiting A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07177937Phase 1 · recruiting A Study of DXC014 in Patients With Advanced Solid Tumors. · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07339176Phase 1/Phase 2 · recruiting Intratumoral N17350 in Advanced Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365241Phase 3 · recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07602855Phase 1/Phase 2 · recruiting A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07661966NA · recruiting Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07796451NA · not yet recruiting Low-Frequency rTMS for Sleep After Thoracoscopic Lung Resection · condition mapped ONTOLOGY_EXACT · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07822880Phase 4 · not yet recruiting A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07835789Phase 2 · not yet recruiting Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer · condition mapped PROBABILISTIC · 11,608 trials mapped (3,446 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836543Phase 2 · not yet recruiting Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07837739recruiting Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00340405completed Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China · condition mapped CURATED_EXACT · 11,608 trials mapped (3,446 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03375320Phase 3 · active not recruiting Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Neuroendocrine Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965689Phase 2 · active not recruiting Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04079712Phase 2 · active not recruiting Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04928846Phase 3 · recruiting A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05009836Phase 3 · active not recruiting Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215548Phase 2 · recruiting Primary Tumor Resection With EGFR TKI for Stage IV NSCLC · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05696782Phase 2 · recruiting Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05745740Phase 1/Phase 2 · not yet recruiting A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06066138Phase 1 · recruiting A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · condition mapped CURATED_BROADER · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06128551Phase 1/Phase 2 · recruiting Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06140836Phase 3 · active not recruiting A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06151574Phase 3 · active not recruiting Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06568939Phase 2 · recruiting A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06712316Phase 2/Phase 3 · recruiting Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06714617Phase 1 · terminated Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06875310Phase 3 · recruiting A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07006727Phase 1 · recruiting Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07028489recruiting Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07100080Phase 2/Phase 3 · recruiting Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) · condition mapped ALIAS · 11,608 trials mapped (3,446 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |